SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid a sharp intraday reversal, prompting discussions about potential market manipulation and the strength of the AI sector following Nvidia's earnings; traders are actively debating whether this pullback represents a buying opportunity or the start of a deeper correction, with some pointing to possible Yen carry trade issues.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing high volatility as traders debate whether recent drops signal a larger market correction or just a temporary pullback, fueled by concerns around AI valuations and potential recession indicators. Community sentiment is mixed, with some anticipating a bounce while others brace for further declines, closely watching key support levels and VIX movements. The conversation includes speculation about the Fed's next moves and the impact of economic data on market direction.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Despite strong earnings, NVIDIA is trending down, sparking debate about an AI bubble. The community is actively discussing whether the drop is a market correction, profit-taking, or manipulation by institutional investors. Some also point to comments from a Fed official raising concerns about valuations as a contributing factor.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending following a strong Q3 earnings report that included raised FY26 guidance and a surge in e-commerce sales, with discussion around its potential move to the Nasdaq. Community talking points include whether Walmart is a safe haven during market volatility and the impact of potential government shutdowns on SNAP benefits and consumer spending at Walmart stores.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing a significant downturn, sparking debates about its role as a store of value and potential for further decline. Community discussions revolve around possible bottom levels, with some anticipating a substantial bounce while others fear a continued slide. The broader market context, including potential impacts from macroeconomic factors and liquidations, is also fueling uncertainty and volatility.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending following a target price increase from UBS and rising memory prices linked to AI data-center demand, fueling discussions about its growth potential. Community members are weighing the bullish outlook against concerns of an overbought condition after the stock's significant year-to-date gains. Discussions also focus on potential short-term pullbacks versus long-term opportunities in the semiconductor space.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MELI is experiencing a significant downturn, with discussions focusing on a recent shelf filing and potential competition from Amazon as possible catalysts. The community is expressing concerns about the stock's performance, with some seeing the dip as a buying opportunity while others are wary of further declines. Broader macroeconomic factors and regional risks in Latin America are also being considered as contributing factors to the volatility.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending due to Bitcoin's price volatility, sparking debates on whether to buy the dip or brace for further declines; some community members point to potential manipulation and significant ETF outflows as bearish signals, while others highlight oversold conditions and historical patterns as reasons for optimism, with key options levels around \$50 also in focus.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending due to discussions around warrant redemptions and their impact on stock dilution, with a deadline approaching soon. The community is debating the company's long-term potential, its management, and comparing it to other rare earth companies, with some expressing concerns about recent performance and others highlighting its strategic partnerships and focus on heavy rare earth elements. News around the company's deal with Solvay and Saudi Arabian Mining Company (Maaden), meant to develop a rare earth refinery, has brought some recent attention.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as it hits fresh 52-week lows, with the community debating whether it's a buying opportunity or if further downside is expected due to its correlation with Bitcoin. Despite the recent price drop, some traders are noting unusual call option activity, suggesting contrarian bullish bets, while others point to potential liquidation levels and debt concerns.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Biogen will obtain exclusive worldwide rights to Vanqua’s investigational drug that targets a protein involved in inflammatory responses.</li><li>Vanqua will receive $70 million upfront payments and will be eligible to receive up to $990 million in milestone payments.</li><li>Biogen will lead all future development, manufacturing, and commercialization efforts for the experimental drug.&nbsp; &nbsp;</li></ul>Biogen Inc. (BIIB) on Friday announced a license agreement with Vanqua Bio granting it exclusive worldwide rights to the latter’s preclinical drug candidate targeting a range of inflammatory disorders.Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.biogen.com/news-releases/news-release-details/biogen-licenses-oral-c5ar1-antagonist-vanqua-bio-expand">deal</a>, Biogen will obtain exclusive worldwide rights to Vanqua’s investigational drug that targets a protein involved in inflammatory responses.<h2 class="st-heading-2">Terms Of The Deal</h2>Vanqua will receive $70 million in upfront payments and be eligible to receive up to $990 million in milestone payments, in addition to tiered royalties on potential net sales, as per the agreement. Biogen will lead all future development, manufacturing, and commercialization efforts of the experimental drug.Jane Grogan, Executive Vice President and Head of Research at Biogen, said that advancing the program will enable it to deepen focus on immunological diseases.Biogen expects to file an application with the U.S. Food and Drug Administration for approval of the candidate in 2027, if results remain supportive. In preclinical studies, the program demonstrated activity as well as a safety and tolerability profile supportive of advancing it into clinical development, the company noted.Last year, Biogen also acquired privately held Human Immunology Biosciences for up to $1.8 billion to expand its immunology portfolio.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> rose 1% on Friday morning at the time of writing. On Stocktwits, retail sentiment around BIIB stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:620/59;" src="data:image/png;base64,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" width="620" height="59" alt="BIIB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 24, 2025 | Source: Stocktwits"><figcaption>BIIB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 24, 2025 | Source: Stocktwits</figcaption></figure>According to Koyfin data, 16 of the 35 analysts covering Biogen rate it ‘Buy’ or higher, while 19 rate it ‘Hold’. The stock has an average price target of $172.55, representing a potential upside of about 14%.BIIB stock is down by 1% this year and by about 18% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-to-acquire-adverum-biotechnologies/cLGJ8N0R3tc">Eli Lilly To Acquire Adverum Biotechnologies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Licenses Vanqua Bio’s Immunology Drug In $1.06B Deal

Biogen will lead all future development, manufacturing, and commercialization efforts for the experimental drug. 

Equity

<ul class="summary-bullets"><li>The Pennsylvania-headquartered company raised its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion.&nbsp;</li><li>The company is banking on strong demand for its high-value product (HVP) components used in GLP-1 drugs for weight loss and diabetes management.&nbsp;</li><li>For Q3, West Pharmaceutical reported adjusted and diluted EPS of $1.92, compared to $1.85 in the same period last year.&nbsp; &nbsp;</li></ul>Shares of West Pharmaceutical Services (WST) soared 12% on Thursday afternoon after the company increased its full-year earnings guidance after its third-quarter earnings beat Wall Street expectations.The Pennsylvania-headquartered company, which manufactures packaging components and delivery systems for injectable drugs and healthcare products, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.westpharma.com/news-releases/news-release-details/west-reports-third-quarter-2025-results">raised</a> its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion.It also hiked its full-year adjusted earnings per share (EPS) outlook to $7.06 to $7.11, up from $6.65 to $6.85, citing strong demand for its high-value product (HVP) components used in GLP-1 drugs for weight loss and diabetes regulation. In Q3, HVP components accounted for 48% of the company's total net sales.The firm, however, flagged that it continues to anticipate $15 million to $20 million in tariff-related costs this year.<h2 class="st-heading-2">CEO Remarks</h2>Chief Executive Eric M. Green stated that several factors drove HVP component sales in Q3. “First, elastomers for GLP-1s had strong growth and now account for 9% of total company sales. We benefit from our longstanding relationships as we partner with our customers in this market, supporting them as they expand their GLP-1 franchises…We expect this market to continue to evolve as there are a number of new early-stage trials seeking to expand the range of indications and treatments using GLP-1s,” Green said.He added that the company, which includes weight-loss drugmakers Eli Lilly and Novo Nordisk among its customers, is also collaborating with customers who are launching new GLP-1 molecules and generics.<h2 class="st-heading-2">Third Quarter Earnings</h2>For the third quarter (Q3), West Pharmaceutical reported adjusted and diluted EPS of $1.96, compared to $1.85 in the same period last year, and above an analyst estimate of $1.68, according to data from Fiscal AI. Net sales increased 7.7% year-over-year to $804.6 million in the quarter.The company reported a 16.3% increase in net sales of its HVP components to $390 million in the quarter. Contract-manufactured products segment net sales, meanwhile, rose 8% to $157.1 million, driven by increased sales of self-injection devices for obesity and diabetes.Evercore ISI analyst Daniel Markowitz raised the firm's price target on West Pharmaceutical to $390 from $350 while keeping an ‘Outperform’ rating on the shares following the earnings call.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/WST">WST stock</a> improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:619/59;" src="data:image/png;base64,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" width="619" height="59" alt="WST's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Oct. 23, 2025 | Source: Stocktwits"><figcaption>WST's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Oct. 23, 2025 | Source: Stocktwits</figcaption></figure>WST stock is down by 5% this year but has risen over 8% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/staar-surgical-stock-rises-after-adjournment-of-stockholders-meeting-to-discuss-proposed-merger-with-alcon/cLG4FXDR3rj">STAAR Surgical Stock Rises After Adjournment Of Stockholders’ Meeting To Discuss Proposed Merger With Alcon</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a West Pharmaceutical Services logo is seen on a mobile phone screen in front of a graph. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

WST Stock Soars After Company Raises Full-Year Guidance On Strong Demand For GLP-1 Drug Components

The Pennsylvania-headquartered company raised its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion. 

Shares of Humana (HUM) rose 3% on Thursday afternoon after the company affirmed its full-year earnings per share guidance provided in July.The insurer stated that it expects adjusted earnings per common share of $17 for the year ending Dec. 31, 2025, and diluted earnings per share of $13.77.The firm also stated that its preliminary 2026 Medicare Advantage (MA) Star Ratings align with the assumptions in its financial planning. As a result, there is no change to the incremental earnings potential for 2025 to 2028. The ratings data provided by the Centers for Medicare and Medicaid Services was inadvertently accessible on CMS Plan Finder for a brief period on Oct. 1, 2025, the company stated.CMS assigns a star rating to Medicare Advantage plans, ranging from one to five, with five being the highest rating. Beneficiaries can use this data to help choose plans, and insurance companies can receive government bonus payments for higher ratings.Humana has about 20% of its members currently enrolled in Medicare plans rated four stars and above for 2026, and 14% of members in 4.5-star plans for 2026, it said.“Based on all information available to date, the company remains confident in its 2026 Individual MA pricing and benefit design, including the expectation that it will double individual MA pre-tax margin in 2026 (excluding Stars), and believes it is positioned to return to membership growth in 2026,” the firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/49071/000004907125000048/hum-20251002.htm">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HUM">HUM stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_02_at_1_48_22_PM_png_d2e549fd89.webp" alt="HUM's Sentiment Meter and Message Volume as of 2 p.m. ET on Oct. 02, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>HUM's Sentiment Meter and Message Volume as of 2 p.m. ET on Oct. 02, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user reported selling their holdings in Humana, citing excessive volatility.<stembedurl>https://stocktwits.com/Felo3179/message/630807403</stembedurl>HUM stock has risen 3% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/immuron-stock-rallies-after-ceo-dismisses-us-pharma-tariff-impact/chCrSSWR3f5">Immuron Stock Rallies After CEO Dismisses US Pharma Tariff Impact, Provides Positive Pipeline Updates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The MyHumana app page is displayed on a smartphone in the Apple App Store in front of the Humana Inc logo on October 30, 2024 in Chongqing, China. (Photo by Cheng Xin/Getty Images)

Humana Stock Rises After Insurer Reaffirms Full-Year Earnings Guidance

The firm also stated that its preliminary 2026 Medicare Advantage Star Ratings align with the assumptions in its financial planning, and as a result, there is no change to the incremental earnings potential for 2025 to 2028.

XRMI
Global X S&P 500 Risk Managed Income

Feed

News

Sentiment

Fundamentals

Info

Latest XRMI News

XRMIGlobal X S&P 500 Risk Managed Income